Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045029 | 0.95 | L3MBTL1 (0.35) | SMYD3 | |
| SCHEMBL1044752 | 0.93 | SMYD3 (0.35) | NPC1SMYD3PPARG | |
| SCHEMBL1043972 | 0.86 | GSK3B (0.35) | — | |
| SCHEMBL1044864 | 0.86 | SMYD3 (0.34) | NPC1SMYD3 | |
| SCHEMBL1042417 | 0.85 | KCNH2 (0.35) | — | |
| SCHEMBL15121628 | 0.84 | L3MBTL1 (0.35) | NPC1PPARG | |
| SCHEMBL1042802 | 0.82 | F2RL3 (0.34) | — | |
| SCHEMBL15121790 | 0.82 | PPARG (0.34) | PPARG | |
| SCHEMBL6526733 | 0.80 | BAZ2A (0.37) | PPARG | |
| SCHEMBL1040331 | 0.80 | HSD11B1 (0.40) | NPC1SMYD3EPHX2ELOVL6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | claimed |
| EP-2271405-A2 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDORXYSTEROID DEHYDROGENASE-1 | Merck Patent GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009135581-A9 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | claimed |
| WO-2009135581-A2 | NOVEL NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 235/4885SMYD3 4839/4885EPHX2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.